Facet Arthroplasty
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 07.01.102 alerts
Get alerted when Policy 07.01.102 changes without checking for updates manually.
Monitor payer policy activity
This policy governs the clinical coverage stance for total facet arthroplasty as an adjunct to neural decompression for lumbar spinal stenosis and related degenerative conditions for Blue Cross Blue Shield - Iowa members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Investigational / Not established
Covered when ALL of the following are met
Evidence is insufficient to determine improvement in net health outcome
Coverage when trial-based criteria are documented
Evidence from IDE randomized trials and interim analyses supports coverage when the following trial‑based clinical criteria are met and documented:
Derived from inclusion criteria of the randomized TOPS IDE trial
Consistent with trial inclusion
Based on TOPS IDE trial procedures and FDA PMA documentation
Interim TOPS trial reports showed higher rates of MCID in ODI and VAS and lower new/worsening neurologic deficits versus fusion
Total facet arthroplasty is investigational and is not covered as an established therapy for lumbar spinal stenosis when performed as an adjunct to spinal decompression. The evidence is insufficient to determine that total facet arthroplasty improves the net health outcome.
Previously studied facet replacement devices with discontinued trials or reported device failures (for example, the Total Facet Arthroplasty System with reported stem fractures, and the ACADIA Facet Replacement System with limited or unfinished reporting and case reports of adverse tissue reactions including cobalt allergy) are considered experimental or unsupported without further justification.
Available clinical evidence—comprised of interim reports from randomized trials, a preliminary unpublished RCT report, and small case series—is limited by short follow-up, incomplete reporting (including primary outcome data from only a portion of randomized patients), and inability to blind participants and evaluators. Given these limitations, the evidence is insufficient to demonstrate an improvement in net health outcome with total facet arthroplasty and the procedure is not supported as medically necessary.
Facet replacement devices or specific indications that lack adequate evidence of safety and effectiveness—including devices from discontinued IDEs or with reports of stem fracture, metal‑on‑metal adverse tissue reactions, or documented cobalt allergy—are considered not medically necessary or experimental unless there are substantive supportive data.
Coding
| No codes listed |
| P220002 | FDA PMA number for TOPS System (Product Code QWK referenced) |
| 0202T | Posterior vertebral joint(s) arthroplasty (e.g. facet joint[s] replacement) including facetectomy, laminectomy, foraminotomy and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine |
Provider Actions / Billing
No policy-level prior authorization specified — verify benefits
This policy does not specify a general prior authorization program for total facet arthroplasty; however, providers must verify member benefits under the applicable contract before scheduling services.
- Benefit verification is required because benefits, exclusions, limitations, or exceptions may vary by contract.
- Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.
Prior authorization required for CPT 0202T
Per payer billing practice, prior authorization is required when reporting CPT 0202T (posterior vertebral joint(s) arthroplasty); include operative and preoperative documentation to support medical necessity.
- CPT 0202T description: posterior vertebral joint(s) arthroplasty including facetectomy, laminectomy, foraminotomy and vertebral column fixation, injection of bone cement when performed, single level, lumbar spine.
- Submit operative report and preoperative documentation with the authorization request.
Compare to decompression with fusion and nerve ablation
Consider standard comparator therapies when selecting treatment: lumbar decompression followed by spinal fusion and nerve ablation techniques are current alternatives.
- Spinal fusion is a common treatment following decompression when conservative therapy fails.
- Nerve ablation techniques are also used to treat lumbar spinal stenosis.
Require ≥6 months of conservative therapy prior to surgical consideration
Document that symptoms persisted despite at least 6 months of conservative therapy before considering arthroplasty; trial protocols enrolled patients after ≥6 months of nonoperative management.
- Examples of conservative therapy: physical therapy, systemic pain management, or local injections/nerve block.
- Conservative therapy duration expected: ≥6 months, consistent with randomized trial inclusion.
Verify individual member benefits and contract exclusions
Verify member benefits and any contract exclusions, limitations, or exceptions prior to authorization or scheduling; coverage is determined by applicable contract language.
- Benefits may vary by contract and this medical policy may not apply to all plans (e.g., FEP).
- Wellmark will determine medical necessity only if the benefit exists and no contract exclusions apply.
Required clinical documentation to support medical necessity
Include specific clinical documentation with any request: indication (e.g., grade I degenerative spondylolisthesis with symptomatic stenosis), prior conservative therapy, device implanted (such as TOPS), operative report, and follow-up outcomes/rationale for arthroplasty versus fusion.
- Document duration and type of conservative therapy (physical therapy, systemic medications, injections/nerve blocks).
- Provide operative report detailing decompression and device implantation and post‑operative follow-up data or rationale referencing comparative trial results.
Investigational status may lead to denial as not medically necessary
Because total facet arthroplasty is considered investigational by this policy, services billed for this intervention may be denied as not medically necessary under the policy.
- Plan pre-authorization and benefit verification do not guarantee payment if the service is deemed investigational per policy language.
Interim/limited evidence may trigger documentation requests or denial
Evidence limitations from interim and partial trial reporting (selection/reporting limitations, incomplete follow-up, trial stoppage) may prompt requests for additional documentation or result in denial if medical necessity is not clearly supported.
- Interim analyses have noted that not all randomized patients were included and that blinding was lacking; trials were stopped early in some cases.
- Provide complete follow-up data and justification when available; incomplete trial reporting increases the likelihood of additional information requests or denial.
Background
Facet arthroplasty involves implantation of a spinal prosthesis intended to restore posterior element structure and function as an adjunct to neural decompression. It is proposed as an alternative to posterior spinal fusion for select patients with facet arthrosis, spinal stenosis, or spondylolisthesis, aiming to stabilize the treated level while preserving motion and potentially reducing adjacent‑level degeneration.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.